458 related articles for article (PubMed ID: 31735286)
21. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy.
Smith C; Zheng W; Dong J; Wang Y; Lai J; Liu X; Yin F
World J Gastroenterol; 2022 Jul; 28(27):3297-3313. PubMed ID: 36158269
[TBL] [Abstract][Full Text] [Related]
22. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
[TBL] [Abstract][Full Text] [Related]
23. Novel and emerging innate immune therapeutic targets for pancreatic cancer.
Wang L; Shureiqi I; Stroehlein JR; Wei D
Expert Opin Ther Targets; 2018 Dec; 22(12):977-981. PubMed ID: 30332892
[No Abstract] [Full Text] [Related]
24. Pancreatic ductal adenocarcinoma: a review of immunologic aspects.
Wachsmann MB; Pop LM; Vitetta ES
J Investig Med; 2012 Apr; 60(4):643-63. PubMed ID: 22406516
[TBL] [Abstract][Full Text] [Related]
25. Promising Therapeutic Approach in Pancreatic Cancer: Metabolism-Related Genes.
Choe S; Kwak W; Kim E; Shin S; Shin M; Koh HJ; Yoon H
Front Biosci (Landmark Ed); 2024 Apr; 29(4):137. PubMed ID: 38682209
[TBL] [Abstract][Full Text] [Related]
26. The role of microbiome in pancreatic cancer.
Li JJ; Zhu M; Kashyap PC; Chia N; Tran NH; McWilliams RR; Bekaii-Saab TS; Ma WW
Cancer Metastasis Rev; 2021 Sep; 40(3):777-789. PubMed ID: 34455517
[TBL] [Abstract][Full Text] [Related]
27. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy.
Torphy RJ; Schulick RD; Zhu Y
Mol Carcinog; 2020 Jul; 59(7):775-782. PubMed ID: 32166821
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive review of the multifaceted role of the microbiota in human pancreatic carcinoma.
Pandya G; Kirtonia A; Singh A; Goel A; Mohan CD; Rangappa KS; Pandey AK; Kapoor S; Tandon S; Sethi G; Garg M
Semin Cancer Biol; 2022 Nov; 86(Pt 3):682-692. PubMed ID: 34051351
[TBL] [Abstract][Full Text] [Related]
29. Implications of the microbiome in the development and treatment of pancreatic cancer: Thinking outside of the box by looking inside the gut.
Yu Q; Jobin C; Thomas RM
Neoplasia; 2021 Feb; 23(2):246-256. PubMed ID: 33418277
[TBL] [Abstract][Full Text] [Related]
30. The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy.
Hilmi M; Delaye M; Muzzolini M; Nicolle R; Cros J; Hammel P; Cardot-Ruffino V; Neuzillet C
Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1129-1142. PubMed ID: 37866368
[TBL] [Abstract][Full Text] [Related]
31. Establishment of Slice Cultures as a Tool to Study the Cancer Immune Microenvironment.
Jiang X; Seo YD; Sullivan KM; Pillarisetty VG
Methods Mol Biol; 2019; 1884():283-295. PubMed ID: 30465211
[TBL] [Abstract][Full Text] [Related]
32. Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle.
Kieler M; Unseld M; Bianconi D; Prager G
Pancreas; 2018 Feb; 47(2):142-157. PubMed ID: 29346215
[TBL] [Abstract][Full Text] [Related]
33. The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression.
Pushalkar S; Hundeyin M; Daley D; Zambirinis CP; Kurz E; Mishra A; Mohan N; Aykut B; Usyk M; Torres LE; Werba G; Zhang K; Guo Y; Li Q; Akkad N; Lall S; Wadowski B; Gutierrez J; Kochen Rossi JA; Herzog JW; Diskin B; Torres-Hernandez A; Leinwand J; Wang W; Taunk PS; Savadkar S; Janal M; Saxena A; Li X; Cohen D; Sartor RB; Saxena D; Miller G
Cancer Discov; 2018 Apr; 8(4):403-416. PubMed ID: 29567829
[TBL] [Abstract][Full Text] [Related]
34. Roles of microbiota in pancreatic cancer development and treatment.
Cruz MS; Tintelnot J; Gagliani N
Gut Microbes; 2024; 16(1):2320280. PubMed ID: 38411395
[TBL] [Abstract][Full Text] [Related]
35. Challenges and Opportunities for Pancreatic Cancer Immunotherapy.
Bear AS; Vonderheide RH; O'Hara MH
Cancer Cell; 2020 Dec; 38(6):788-802. PubMed ID: 32946773
[TBL] [Abstract][Full Text] [Related]
36. Impact of gut microbiome in the development and treatment of pancreatic cancer: Newer insights.
Bangolo AI; Trivedi C; Jani I; Pender S; Khalid H; Alqinai B; Intisar A; Randhawa K; Moore J; De Deugd N; Faisal S; Suresh SB; Gopani P; Nagesh VK; Proverbs-Singh T; Weissman S
World J Gastroenterol; 2023 Jul; 29(25):3984-3998. PubMed ID: 37476590
[TBL] [Abstract][Full Text] [Related]
37. Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review).
Huang X; Li M; Hou S; Tian B
Int J Oncol; 2021 Dec; 59(6):. PubMed ID: 34738624
[TBL] [Abstract][Full Text] [Related]
38. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
39. Strategies to relieve immunosuppression in pancreatic cancer.
Schnurr M; Duewell P; Bauer C; Rothenfusser S; Lauber K; Endres S; Kobold S
Immunotherapy; 2015; 7(4):363-76. PubMed ID: 25917628
[TBL] [Abstract][Full Text] [Related]
40. Current advances in immunotherapy for pancreatic cancer.
Uram JN; Le DT
Curr Probl Cancer; 2013; 37(5):273-9. PubMed ID: 24331182
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
